• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cn-15 * adverse effects of bevacizumab in brain tumor patients
CONCLUSION: The range of toxicities was similar to other reports. Interestingly, hypertension was the most common adverse effect and was often not treated. The high incidence of lymphocytopenia may have implications for combination with immunotherapies. These findings underscore the need to develop predictive models to identify patients at high risk for serious treatment-related toxicities.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Pawar, T., Ladha, H., Mandel, J., Gilbert, M., O'Brien, B., Hamza, M., Armstrong, T. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - March 9, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Conclusion: In ROCKET AF, a history of cancer was associated with a higher risk of bleeding and non-cardiovascular death, but not ischemic events. The relative efficacy and safety of rivaroxaban compared with warfarin were not significantly different in patients with and without a history of cancer. The results of this study are exploratory and should be taken in context of the study population, which may not be generalizable to those with advanced malignancy. Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. PMID: 30219887 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C Tags: Eur Heart J Qual Care Clin Outcomes Source Type: research

Incidence rates of cardiovascular outcomes in a community ‐based population of cancer patients
ConclusionsIn a population of patients with cancer not exposed to TKIs, cardiovascular risk factors and outcomes are very common, regardless of cancer type. These data can inform the evaluation of potential excess cardiovascular risks from new interventions.
Source: Cancer Medicine - October 29, 2019 Category: Cancer & Oncology Authors: Rajeev Masson, Lina Titievsky, Douglas A. Corley, Wei Zhao, Alfredo R. Lopez, Jennifer Schneider, Jonathan G. Zaroff Tags: ORIGINAL RESEARCH Source Type: research

Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
Curr Oncol. 2022 Aug 24;29(9):6077-6090. doi: 10.3390/curroncol29090478.ABSTRACTArterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy. The ATE definition included peripheral arterial embolism/thrombosis, ischemic stroke and coronary events. A total of 354 aUTC patients were analyzed. Most patients (95.2%) received platinum-based c...
Source: Current Oncology - September 22, 2022 Category: Cancer & Oncology Authors: Aristotelis Bamias Kimon Tzannis Roubini Zakopoulou Minas Sakellakis John Dimitriadis Alkistis Papatheodoridi Loukianos Rallidis Panagiotis Halvatsiotis Anna Tsiara Maria Kaparelou Efthymios Kostouros Despina Barbarousi Konstantinos Koutsoukos Evangelos F Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13